Premier Nutra Pharma Inc.

Warning LetterOpen

United StatesFEI 3017303868Issued Dec 9, 2022Division of Pharmaceutical Quality Operations IV

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3017303868.

Violations0

Issue DateDec 9, 2022

Product TypeDrugs

StatusOpen

Letter Details

Firm: Premier Nutra Pharma Inc.
Location: United States
FEI Number: 3017303868
Country: United States
Issue Date: December 09, 2022
Issuing Office: Division of Pharmaceutical Quality Operations IV
Product Type: Drugs
Status: Open

Summary

Based on limited metadata, Premier Nutra Pharma Inc. received an FDA Warning Letter on December 9, 2022, regarding drug products. Without access to the full letter text or specific subject line, the exact nature of the violations cannot be determined from the available information. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not identified in the metadata provided. Additional documentation would be needed to detail the specific compliance violations cited.

Premier Nutra Pharma Inc. FDA Warning Letter, December 9, 2022